Pharmaceutical Company
Appears in 4 stories
Building real-world evidence for Cobenfy; planning UK launch in 2026
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated 27 minutes ago
Incumbent oral TYK2 competitor via Sotyktu; a key benchmark for Takeda
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated May 15
Maker of competing oral psoriasis drug Sotyktu, which ICOTYDE outperformed in head-to-head trials
For two decades, the most effective treatments for moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions that many patients refused or abandoned. On March 18, 2026, the Food and Drug Administration (FDA) approved ICOTYDE, a once-daily pill that blocks the interleukin-23 (IL-23) receptor with the precision of an injectable biologic. In clinical trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of a placebo.
Updated Mar 18
Awaiting FDA decision on Sotyktu expansion into psoriatic arthritis
For most of the past decade, people with psoriatic arthritis who wanted a pill instead of an injection had one real option: Janus kinase (JAK) inhibitors, a class of oral drugs that the Food and Drug Administration (FDA) slapped with its strongest safety warning in 2021 after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death. On March 6, the FDA reached its decision deadline on whether to approve the first oral drug from a different class entirely—Bristol Myers Squibb's Sotyktu (deucravacitinib), a selective tyrosine kinase 2 (TYK2) inhibitor—for adults with active psoriatic arthritis, a condition that causes painful joint inflammation in roughly 1.5 million Americans.
Updated Mar 6
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
